November - 2019

Companies in the News

Gossamer Bio Announces Clinical Trial Collaboration Agreement With Merck to Evaluate GB1275 in Combi

Phase 1/2 trial ongoing with multiple patients dosed in GB1275 monotherapy dose escalation – GB1275 granted Orphan Drug Designation for...

Effector Therapeutics Initiates Phase 1/2 Safety and Efficacy Study of Zotatifin (EFT226) in Patient

Program addresses aggressive cancers with RTK (HER2, ERBB3, FGFR1, FGFR2) and KRAS mutations SAN DIEGO, November 5, 2019 — eFFECTOR...

Gritstone Oncology Announces Data on Novel Shared Tumor-Specific Neoantigens Identified by its EDGE

EMERYVILLE, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company...